 | ||||||
| Ebola | ||||||
| NEWS | ||||||
| Novavax, Inc. (NVAX) Reaches $2.14 After 6.00% Down Move; Shorts at SHANGRI-LA ASIA LTD ... It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Investors sentiment increased to 1.26 in Q3 2017. Its up 0.24, from 1.02 in ...
| ||||||
| See more results | Edit this alert | ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
Tidak ada komentar:
Posting Komentar